Higher provisions for legal matters included a charge of £141m at the end of 2004, reflecting a change in the company’s accounting method of provisions for potential claims against GSK.
Earnings per share dropped slightly to 75 pence on sales down 5% to £20.36bn
JP Garnier, chief executive officer, was however upbeat for the future: ‘These results confirm the success with which GSK has navigated a difficult year, absorbing over £1.5bn of lost sales to generics and still managing to grow the business. The continuing success of our key products means we can now look forward to a good performance in 2005.’
Peter Terry joins the North West advisory team
The average cost of fraud increased 35.4% to £3.9m in 2016, compared to 2015 data
Tallat Mahmood appointed to corporate finance team of Top 20 firm
Andrew Tyrie airs views on the Finance Bill, 'Making Tax Policy Better' report, and Brexit